Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis

Meta-analyses provide the strongest level of evidence in clinical research by pooling data from multiple studies. This systematic review and meta-analysis by Tan, Dampil, and Marquez evaluated semaglutide's efficacy and safety specifically for weight loss in people with obesity who do not have diabetes.

The researchers systematically identified and analyzed all qualifying clinical trials of semaglutide for weight loss in non-diabetic populations. By pooling data across studies, the meta-analysis provided a more precise and reliable estimate of semaglutide's effects than any single trial could offer.

The meta-analysis confirmed semaglutide's strong efficacy for weight loss in non-diabetic obesity, with consistent results across the pooled studies. Importantly, the safety profile was also favorable, with no unexpected safety signals emerging from the combined data.

This high-level evidence strengthens the case for semaglutide's widespread clinical use in obesity management. For patients without diabetes who are seeking effective weight loss treatments, this meta-analysis provides robust reassurance that semaglutide delivers meaningful results with a well-characterized safety profile.